Results summary | View all lists in L2L MDB | View all genes in N04BC.profile.u50 |
List Name | Description | Total probes |
Expected matches |
Actual matches |
Fold Enrichment |
Binomial p-value |
---|---|---|---|---|---|---|
et743_sarcoma_resist_dn | Constiutively down-regulated in three sarcoma cell lines resistant to Et-743 compared to six sensitive lines | 8 | 0.02 | 2 | 101.14 | 1.69e-04 |
as3_hek293_dn | Downregulated in HEK293 cells by treatment with arsenite | 12 | 0.03 | 2 | 67.42 | 3.97e-04 |
mmc_res_xenografts_up | Up-regulation is correlated with resistance of human cancer xenografts to mitomycin C | 14 | 0.03 | 2 | 57.79 | 5.45e-04 |
hypoxia_fibro_young_up | Upregulated by hypoxia in normal fibroblasts from young, but not old, donors (Table 1) | 15 | 0.04 | 2 | 53.94 | 6.28e-04 |
bay_pbmc_2hr_up | Up-regulated at 2 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 606 | 1.50 | 7 | 4.67 | 9.00e-04 |
alk5_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 5 | 5.83 | 1.87e-03 |
alk5_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 5 | 5.83 | 1.87e-03 |
il2_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 510 | 1.26 | 6 | 4.76 | 1.88e-03 |
bay_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 544 | 1.34 | 6 | 4.46 | 2.59e-03 |
bleo_human_lymph_high_4hrs_up | Up-regulated at 4 hours following treatment of human lymphocytes (TK6) with a high dose of bleomycin | 32 | 0.08 | 2 | 25.28 | 2.88e-03 |
bcnu_glioma_nomgmt_48hrs_dn | Down-regulated in an MGMT-deficient glioma cell line (A172) at 48 hours following treatment with BCNU | 50 | 0.12 | 2 | 16.18 | 6.92e-03 |
brg1_h1299_up | Up-regulated by transient expression of BRG1 in H1299 lung cancer cells with mutant, inactive BRG1 | 50 | 0.12 | 2 | 16.18 | 6.92e-03 |
bay_pbmc_6hr_up | Up-regulated at 6 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 475 | 1.17 | 5 | 4.26 | 7.01e-03 |
pubertal_mammary_3-4wks_dn | Down-regulated > 1.5-fold in the developing mouse mammary gland between 3 and 4 weeks of age. | 55 | 0.14 | 2 | 14.71 | 8.32e-03 |
serum_fibroblast_core_dn | Core group of genes consistently down-regulated following exposure to serum in a variety of human fibroblast cell lines (higher expression in quiescent cells, not cell-cycle dependent) | 319 | 0.79 | 4 | 5.07 | 8.55e-03 |